Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry... Show more
Colgate-Palmolive operates primarily in oral care, personal care, home care, and pet nutrition, with a global footprint that spans developed and emerging markets. The company maintains strong brand equity in categories such as toothpaste and pet food through Hill’s Science Diet and Prescription Diet lines. Its competitive advantages include extensive distribution networks, science-based innovation pipelines, and a diversified portfolio that reduces reliance on any single region or product line. Medium-term positioning centers on premiumization strategies, supply-chain simplification, and enhanced digital and omnichannel capabilities to capture shifting consumer preferences toward higher-value offerings. Structural risks include exposure to private-label competition in mature markets and the need to sustain market share gains amid slower overall category expansion.
Quarterly earnings releases remain central, with investors focused on organic sales trends, gross margin recovery, and advertising effectiveness. The company plans continued innovation launches, particularly in Asia Pacific and North America oral care, which could support sequential share gains. Regulatory or trade developments, including tariffs, may influence cost structures and pricing power. Analyst rating revisions and price-target updates from firms such as Barclays, JPMorgan, and Citigroup will likely shape sentiment; recent actions show mixed but generally constructive views, with some targets raised amid 2026 staples outlook discussions. Capital allocation priorities, including share repurchases and dividend maintenance, provide additional visibility. Progress on the 2030 strategy, including productivity programs, could serve as a longer-term catalyst if execution delivers margin expansion.
The consumer staples sector faces moderating demand growth and heightened price sensitivity among households. Inflationary pressures on raw materials and logistics remain relevant, as do foreign exchange movements given the company’s international revenue exposure. Interest rate trajectories influence consumer borrowing costs and overall spending patterns in personal care and pet nutrition. Geopolitical developments and evolving trade policies, including tariffs, directly affect supply chains and input costs. Technology adoption, particularly in e-commerce and data analytics, offers opportunities for demand generation, while regulatory climates around sustainability and product claims continue to evolve. These forces connect closely to Colgate-Palmolive’s model through its reliance on stable consumer staples demand and its ability to offset cost pressures via pricing and operational efficiencies.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. Trend Prediction Engine
Colgate-Palmolive’s 2030 strategy focuses on five pillars aimed at delivering consistent compounded earnings per share growth through organic sales expansion, operational efficiencies, and free cash flow generation. Key long-term themes include market expansion in emerging regions, continued premiumization across oral and pet nutrition segments, and technology transitions supporting omnichannel and analytics capabilities. Margin sustainability will depend on productivity gains offsetting raw material and tariff-related headwinds. Competitive threats from agile private-label players and evolving consumer preferences toward sustainability represent ongoing considerations. Capital allocation priorities emphasize balanced returns to shareholders alongside investment in innovation. Consensus analyst expectations for low- to mid-single-digit EPS growth and modest sales expansion in 2026 reflect a cautiously constructive view on the company’s ability to navigate the current environment while advancing its strategic agenda.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a maker of oral, personal, and household products
Industry HouseholdPersonalCare
A.I.dvisor indicates that over the last year, CL has been closely correlated with PG. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if CL jumps, then PG could also see price increases.
The Moving Average Convergence Divergence (MACD) for CL turned positive on August 13, 2026. Looking at past instances where CL's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where CL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on CL as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CL moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CL advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 282 cases where CL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CL's P/B Ratio (312.500) is very high in comparison to the industry average of (24.458). P/E Ratio (36.587) is within average values for comparable stocks, (54.648). Projected Growth (PEG Ratio) (1.790) is also within normal values, averaging (3.031). Dividend Yield (0.023) settles around the average of (0.034) among similar stocks. P/S Ratio (3.557) is also within normal values, averaging (2.437).